Pluvia Endo

Pluvia Endo is a clinical-stage medical technology company focused on developing minimally invasive endoscopic treatments for metabolic diseases, including Type 2 Diabetes and obesity. The company's lead technology is a proprietary hydrogel-based system designed to coat the duodenal mucosa, effectively mimicking the metabolic benefits of gastric bypass surgery. By creating a temporary, reversible barrier in the proximal small intestine, the treatment modulates nutrient-gut interactions to improve glycemic control and induce weight loss. Pluvia Endo aims to provide a scalable, outpatient alternative to invasive bariatric procedures. The company is currently advancing its platform through clinical evaluation to address the global epidemic of metabolic syndrome.